Mus musculus Genome sequencing and assembly
Osteoporosis, a prevalent degenerative disease in the aging population, is a significant public health challenge. This study investigates the effects of Myricitrin, a compound derived from Myrica rubra, on osteoclast differentiation and bone mass loss, particularly in an ovariectomized (OVX) mouse model.Myricitrin significantly inhibited osteoclast differentiation in RAW264.7 cells and bone marrow macrophages (BMMs), as evidenced by decreased expression of key genes and proteins involved in osteoclastogenesis. It altered cytokine and chemokine signaling pathway gene expressions and suppressed the MAPK pathway, a pivotal regulator in osteoclast differentiation. In vivo, Myricitrin demonstrated a reduction in OVX-induced bone mass loss. These findings suggest Myricitrin's potential as a therapeutic agent against osteoporosis, warranting further exploration into its clinical applications and mechanisms.